Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.

Trial Details

NCT ID
NCT05922930
Phase
PHASE1 / PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • TROP2-CAR-NK
  • Cyclophosphamide
  • Fludarabine
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Subjects must be 18 years or older.
  • Subjects must be willing and able to provide informed consent.
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • A female participant is eligible to participate if at least one of the following conditions applies:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →